Bruker (NASDAQ:BRKR) Price Target Lowered to $57.00 at Stifel Nicolaus

Bruker (NASDAQ:BRKR - Get Free Report) had its target price lowered by research analysts at Stifel Nicolaus from $70.00 to $57.00 in a report issued on Friday,Benzinga reports. The firm currently has a "hold" rating on the medical research company's stock. Stifel Nicolaus' price target would indicate a potential upside of 12.32% from the stock's current price.

Other equities research analysts have also issued reports about the company. Barclays reduced their price objective on Bruker from $69.00 to $65.00 and set an "overweight" rating for the company in a research note on Monday, February 10th. Bank of America lifted their price target on Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a research note on Friday, December 13th. The Goldman Sachs Group raised shares of Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price objective for the company in a research note on Thursday, December 5th. Wells Fargo & Company dropped their target price on shares of Bruker from $78.00 to $75.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 6th. Finally, TD Cowen reduced their price target on shares of Bruker from $72.00 to $70.00 and set a "hold" rating for the company in a research report on Wednesday, November 6th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $70.50.

Bruker Price Performance

Shares of NASDAQ BRKR traded up $0.71 during mid-day trading on Friday, reaching $50.75. 1,557,884 shares of the company traded hands, compared to its average volume of 1,625,303. Bruker has a fifty-two week low of $48.07 and a fifty-two week high of $94.86. The firm has a market cap of $7.69 billion, a PE ratio of 24.40, a price-to-earnings-growth ratio of 3.81 and a beta of 1.16. The stock has a fifty day simple moving average of $57.14 and a 200-day simple moving average of $60.24. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.52% and a net margin of 9.41%. Equities research analysts anticipate that Bruker will post 2.4 EPS for the current fiscal year.

Institutional Trading of Bruker

Institutional investors have recently bought and sold shares of the company. Gordian Capital Singapore Pte Ltd purchased a new stake in shares of Bruker during the 4th quarter worth about $234,000. EDENTREE ASSET MANAGEMENT Ltd increased its holdings in Bruker by 11.2% in the fourth quarter. EDENTREE ASSET MANAGEMENT Ltd now owns 158,000 shares of the medical research company's stock worth $9,262,000 after buying an additional 15,900 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Bruker by 17.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 356,969 shares of the medical research company's stock valued at $20,926,000 after acquiring an additional 52,214 shares during the last quarter. Voloridge Investment Management LLC grew its position in Bruker by 179.6% in the fourth quarter. Voloridge Investment Management LLC now owns 18,906 shares of the medical research company's stock worth $1,108,000 after acquiring an additional 12,145 shares in the last quarter. Finally, Two Sigma Advisers LP grew its position in Bruker by 406.1% in the fourth quarter. Two Sigma Advisers LP now owns 140,700 shares of the medical research company's stock worth $8,248,000 after acquiring an additional 112,900 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.